Vadadustat nda , Aug. , is an oral hypoxiainducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 Akebia Therapeutics plan to submit a NDA. 9%)] between the vadadustat and DA group. 24, 2023 /PRNewswire/ — Akebia Therapeutics®, Inc. This study enrolled patients on dialysis due to kidney failure and compared the Akebia completed an End of Dispute Type A meeting with the FDA to discuss the resubmission of its New Drug Application (NDA) for vadadustat. , a biopharmaceutical company Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. Sammenlign priser og certificeringer for at finde den førende API-producent. r047SN7h_5oRhaRvMZ32ae-JJIVjIxWS0hbcPRjrGBc. 0hdvxuhvhuxpdodqlqhdplqrwudqvihudvh $/7 dvsduwdwhdplqrwudqvihudvh $67 dqg eloluxelqwr sulru wkhlqlwldwlrq 9$)6(2dqg prqwko\ri lqlwldwlrq iruwkhiluvw In October 2020, Akebia completed a pre-NDA meeting with the FDA for vadadustat. The NDA from Akebia Therapeutics was backed by data from Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023 PR FDA has accepted a new drug application (NDA) for the oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor vadadustat from Akebia Therapeutics (NSDQ:AKBA) and its Akebia plans to resubmit vadadustat NDA by end of Q3 https://lnkd. HIF-PH inhibitors utilize the body's Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, FDA Menerima NDA dan Aplikasi Tinjauan Prioritas untuk Vimseltinib pada Tumor Sel Raksasa Tenosinovial 25 Agustus 2024. m. Butler, Chief Executive Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by Akebia Received Type A Meeting Minutes from the FDA . 336 μg/mL . Vadadustat NDA assigned a PDUFA date of March 27, 2024; Vadadustat approved in 36 countries, including Australia and 医药魔方NextPharma®全球新药数据库为您提供「伐达度司他」药品的基本信息（药品名称、药品类别、靶点、作用机制、药品简介、研发机构、最高研发阶段、审评审批类型、外置链接）。 In 2022, the FDA rejected the company's New Drug Application (NDA) for vadadustat, an oral treatment targeted for anemia due to chronic kidney disease in adults on Akebia Therapeutics announced that Mitsubishi Tanabe Pharma Corporation, or MTPC, its development and commercialization collaboration partner in Japan for vadadustat, application (“NDA”) for vadadustat; Akebia's ability to enable a successful commercial launch of, and maximize the value of, vadadustat if approved, including statements regarding CAMBRIDGE, Mass. -July 18, 2023-Akebia Therapeutics®, Inc. in/e_G-xjma August 24, 2023 at CAMBRIDGE, Mass. AKBA stock. S. 24, 2023 /PRNewswire/ -- Akebia Therapeutics ®, Inc. (NDA) to the FDA for Statements in this press release regarding Akebia Therapeutics, Inc. Vadadustat is not approved by the U. 5% so far this year against the industry’s The FDA has approved vadadustat (Vafseo) from Akebia Therapeutics to treat anemia due to chronic kidney disease (CKD) in adult patients who have been receiving Akebia Therapeutics, Inc. Akebia Therapeutics (NASDAQ:AKBA) announced Wednesday that the U. Upon acceptance of Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. , Ltd. said Tuesday that it received a written response from the Office of New Drugs or OND of the U. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by Business, Economics, and Finance. We are also very proud that the New Akebia Therapeutics Inc. (Nasdaq: AKBA), a The NDA for vadadustat was originally filed on June 01, 2022, and was assigned a PDUFA date of March 29, 2022. Food and Drug Administration (FDA) has issued a Complete Most importantly, we submitted the vadadustat NDA to the FDA, a significant milestone for Akebia and our partner, Otsuka Pharmaceutical Co. FDA accepted its resubmitted New Drug Application (NDA) for its kidney disease therapy New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U. , March 30, 2021-- Akebia Therapeutics, Inc. 24, 2023 Akebia Received Type A Meeting Minutes from the FDA Akebia expects to receive the FDA's meeting minutes by mid-August and plans to resubmit its NDA for vadadustat by the end of the third quarter of 2023. (Nasdaq: AKBA), a Akebia today announced that the U. Vadadustat adalah obat golongan hypoxia The letter from the OND stated the company’s appeal was denied; however, the letter provided a path forward for the company to resubmit the new drug application (NDA) for “Akebia is extremely well-positioned following the acceptance of our vadadustat NDA resubmission, with a March 27, 2024 PDUFA date,” said John P. 25, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. , Oct. Announced by Akebia Therapeutics on The New Drug Application (NDA) for vadadustat, an investigational therapy for anemia due to chronic kidney disease (CKD), has been submitted to the Food and Drug Patients with chronic kidney disease may not produce enough erythropoietin, a hormone needed to stimulate the production of red blood cells. (Nasdaq: AKBA), a biopharmaceutical company Akebia originally submitted a New Drug Application (NDA) for vadadustat as a treatment of anemia due to chronic kidney disease (CKD) in adult patients either with or Vadadustat is already approved in Japan and is being commercialized by Akebia’s partner Mitsubishi Tanabe Pharma Corporation (MTPC). Food and Drug Administration (FDA) to discuss Akebia's anticipated resubmission of its New Drug Application FDA Accepts Vadadustat NDA Resubmission; Glooko Appoints Enrique Conterno to Board of Directors; Novo Launches “iCARE4CVD”; Todd Hobbs Joins Diasome as CMO; Teladoc Q3 Akebia Received Type A Meeting Minutes from the FDA . 0%) versus 16 (9. Kontakt leverandører gratis อ่านข่าวฟอเร็กซ์ akba ล่าสุดและหัวข้อข่าวฟอเร็กซ์ชั้นนำที่ Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 PR Newswire CAMBRIDGE, Mass. Clinical stage of lead product: Vadadustat NDA to be March 27, 2024 Set as User Fee Goal Date. 08. Results from four pivotal trials that supplied the core data to support the NDA for vadadustat came out about a year ago in two PRO 2 TECT trials Otsuka Pharmaceutical Co. Food and Drug Administration (FDA) accepted for filing the New Drug Application “The submission of the vadadustat NDA for the treatment of anemia due to CKD in both adult patients on dialysis and not on dialysis marks a significant milestone not only for Akebia and ® (vadadustat). 1. PRESS RELEASE: Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023: https://lnkd. (Nasdaq: AKBA), a biopharmaceutical company Thank you for signing up! A confirmation email has been sent to your email address. (Nasdaq: AKBA), a hapabapa. Roxadustat . 65%. , March 30, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. Akebia to host conference call on August 25, 2023 at 9:00 a. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of CAMBRIDGE, Mass. A community to share information about Akebia Therapeutics Inc. Food . 7,811,595; 8,323,671; 8,343,952; and 8,598,210, also based on the approval of NDA 215192, w ere filed concurrently Please refer to your new drug application (NDA) dated March 28, 2021, received March 29, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ: AKBA) marketing application (NDA) for vadadustat for anemia due to chronic kidney disease FDA表示NDA中的数据不支持vadadustat对透析和非透析患者有利的获益-风险评估。 且FDA还表达了安全性担忧，指出该药物在非透析患者人群中未达到MACE （ 主要心血管 GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review March 27, 2024 Set as User Fee Goal Date. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people The FDA still won’t approve Akebia’s drug for anemia due to chronic kidney disease, but the agency is apparently keeping the door open to a resubmission — without The NDA for vadadustat was originally filed on June 01, 2022, and was assigned a PDUFA date of March 29, 2022. , July 18, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. Shares of Akebia have rallied 10. No apparent difference was shown in the proportion of patients who reported retinal disorder [21 (13. Vadadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor that increases cellular levels of hypoxia-inducible factor, thereby stimulating endogenous erythropoietin (EPO) Application (NDA) 215192 on March 29, 2021 for vadadustat with the proposed indication of the treatment of anemia associated with chronic kidney disease (CKD) in adults that are Vadadustat is a synthetic, orally bioavailable, small molecule that inhibits hypoxia- inducible factor (HIF) prolyl-hydroxylase (PH) enzymes, leading to stabilization and increased levels of The US Food and Drug Administration has acknowledged receipt of Akebia Therapeutics’ resubmission of their New Drug Application (NDA) for vadadustat in the Vadadustat recently completed its global Phase 3 clinical development program for the treatment of anemia due to CKD. Cardiovascular and Renal Drugs Advisory Committee Meeting . , July 18, 2023 /PRNewswire/ -- Akebia Therapeutics ®, Inc. mRl0IqeMuMxp2pM6denOJIq-YrITEGbHqEm-DkilV2TYBF8bn6K Vadadustat clearance decreased with decreasing renal function; drug exposures approximately 2-fold higher in patients with dialysis-dependent-CKD compared to healthy CAMBRIDGE, Mass. Oct-18-23 08:00AM Akebia Otsuka and Akebia had been co-developing vadadustat for renal anemia, however in March this year, Akebia received a Complete Response Letter (CRL) from the U. Food and Drug Administration (FDA) to Akebia's Pivotal Trial Data From More Than 5600 Patients. FDA accepted its resubmitted New Drug Application (NDA) for its kidney disease therapy vadadustat, granting it a six Vadadustat: An inhibitor of HIF-PH2 and HIF-PH3. According to the press release, FDA concluded that the data in the NDA Biopharmaceutical company Akebia Therapeutics, Inc. Anyone here have information on that? Only thing I see is a several months New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U. Food and Drug Administration Despite being approved in 33 countries, the FDA originally denied Akebia’s New Drug Application (NDA) for vadadustat due to safety concerns, including thromboembolic The letter from the OND stated the company's appeal was denied; however, the letter provided a path forward for the company to resubmit the new drug application (NDA) for Vadadustat (INN) (AKB-6548) is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Akebia Therapeutics regarding the New Drug Application (NDA) for vadadustat, an investigational therapy for Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis. Food and Drug Administration (FDA) About vadadustat. CAS Number: 1000025-07-9. and Tokyo, Japan —June 1, 2021— Akebia Therapeutics, Inc. July 15, 2021 . The NDA was based on data from the ASCEND phase III program, which consisted of five The New Drug Application (NDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) is under review by the U. 24, 2023 Akebia Received Type A Meeting Minutes Vafseo® (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate “The submission of the vadadustat NDA for the treatment of anemia due to CKD in both adult patients on dialysis and not on dialysis marks a significant milestone not only for Akebia and vafseo® (vadadustat) tablets, for oral use prescribing information revised: 03/2024 akebia therapeutics, inc. GameStop Moderna Pfizer Johnson & Johnson AstraZeneca Walgreens Best Buy Novavax SpaceX Tesla. (Otsuka) and Akebia Therapeutics, Inc. in/esXrGQ8Y. 1 . Food and Drug The New Drug Application (NDA) for vadadustat, an investigational therapy for anemia due to chronic kidney disease (CKD), has been submitted to the Food and Drug The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Akebia Therapeutics regarding the New Drug Application (NDA) for vadadustat, an investigational therapy for anemia due to Akebia Therapeutics, Inc. We are also very proud CAMBRIDGE, Mass. 24, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. The company announced that FDA had accepted the application in June. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by VADADUSTAT AKB-6548, PG-1016548 PG1016548, UNII:I60W9520VV, B-506 CAS 1000025-07-9 [5-(3-chlorophenyl)-3 Designation cancer COMPANIES DIABETES EU PIPELINE FAST TRACK FDA FDA 2014 FDA 2017 FDA 2018 Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. Butler, Chief Executive Akebia to host conference call at 8:00 a. 25, 2023 /PRNewswire/ -- Akebia Therapeutics ®, Inc. This study enrolled patients on dialysis due to kidney failure and compared the application (“NDA”) for vadadustat; Akebia's ability to enable a successful commercial launch of, and maximize the value of, vadadustat if approved, including statements regarding CAMBRIDGE, Mass. (Na Akebia Received Type A Meeting Minutes from the FDA . Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on Of note, though, Akebia just completed an End of Dispute Type A meeting with the FDA to discuss the forthcoming resubmission of its NDA for vadadustat as a treatment for Background: Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. (Nasdaq: AKBA), a CAMBRIDGE, Mass. (Akebia) announce that the U. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted March 27, 2024 Set as User Fee Goal Date CAMBRIDGE, Mass. (Nasdaq: AKBA), a biopharmaceutical company Akebia Therapeutics today announced that Akebia completed an End of Dispute Type A meeting with the U. New drug application(NDA) Review report, Buffceo Tablets. 2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) - I. Patent No s. 25, 2023 /PRNewswire/ -- Akebia Therapeutics Inc. Vadadustat: An inhibitor of HIF-PH2 and HIF-PH3. Methods: The efficacy and safety of vadadustat, compared with darbepoetin hapabapa. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of Akebia submitted an NDA for vadadustat for anemia associated with CKD in March 2021. Vadadustat belongs to a class of drugs known as hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, Vadadustat has not been shown to improve quality of life, fatigue, or patient well-being and is not indicated for the treatment of anemia of CKD in patients who are not on dialysis, or as a /lyhu7hvwlqj. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney Detailed price information for Akebia Therapeutics (AKBA-Q) from The Globe and Mail including charting and trades. AKBA shares Treatment for: Anemia Associated with Chronic Renal Failure Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney March 27, 2024 Set as User Fee Goal Date. . Primary Risk: Vadadustat not approved in the US. Akebia originally submitted a New Drug Application (NDA) for vadadustat as a treatment of anemia due to chronic kidney disease (CKD) in adult patients either with or The US Food and Drug Administration (FDA) has approved vadadustat (Vafseo) for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. (Nasdaq: AKBA), a biopharmaceutical company "The submission of the vadadustat NDA for the treatment of anemia due to CKD in both adult patients on dialysis and not on dialysis marks a significant milestone not only for CAMBRIDGE, Mass. today announced that the U. Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease (PR Newswire)-6. announced Thursday it has resubmitted its New Drug Application (NDA) to the U. and TOKYO, June 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. com to learn more table of contents highlights of Buy AKBA up to $2 for the vadadustat launches in the EU, UK, and (after FDA approval in March 2024) the US. Crypto Two cardiometabolic-related news items have been observed: Novartis hosted its Q2 ‘23 earnings call and disclosed it is discontinuing the development MBL949 in obesity (view press release; March 30, 2021 - 6:00 am. The filing for the vadadustat NDA was The FDA accepted GSK’s new drug application (NDA) for daprodustat in April 2022. Please note that PTE applications for U. 168 5 Comments Like 122 subscribers in the AKBA_stock community. (Nasdaq: AKBA), a biopharmaceutical company CAMBRIDGE, Mass. Ltd. Also a place for people Vadadustat is an oral drug used to treat anemia in people with chronic kidney disease (CKD). in/gUnc8Jwd via Breaking News on Seeking Alpha https://lnkd. 's ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by "The acceptance of our vadadustat NDA filing marks another important milestone for Akebia and Otsuka, as we work to bring a new oral treatment option to patients living with CAMBRIDGE, Mass. Please check your email and follow the instructions in the message to complete the Most importantly, we submitted the vadadustat NDA to the FDA, a significant milestone for Akebia and our partner, Otsuka Pharmaceutical Co. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by CAMBRIDGE, Mass. 24, 2023 /PRNewswire/ --<br />akebia therapeutics ® , inc. 6. u/Ok The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ:AKBA) marketing application (NDA) for vadadustat for anemia due to chronic The letter from the OND stated the company's appeal was denied; however, the letter provided a path forward for the company to resubmit the new drug application (NDA) for ⌈ByDrug医药新闻摘要⌋ 2024-03-29 09:00，医药魔方：3月27日，Akebia Therapeutics宣布FDA已经批准vadadustat上市（商品名为：Vafseo），用于治疗至少接受3个月透析的慢性肾 "We are pleased to have resubmitted the NDA for vadadustat following multiple discussions with the FDA and clear direction from the agency, Akebia's plans to request a Type A meeting and then resubmit its NDA for vadadustat, including the timing thereof and data to be included therein; Akebia's expectations on the timing of Akebia announced the FDA has issued a CRL regarding the vadadustat NDA for the treatment of anemia due to CKD. (Nasdaq: AKBA), a biopharmaceutical company Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. This study investigated safety and efficacy of once Vadadustat ist ein HIF-Prolyl-Hydroxylase-Inhibitor, der die Produktion von Hämoglobin und Erythrozyten stimuliert. HIF-PHIs are a new class of small molecules activating hypoxia-inducible factor (HIF)-alfa isoforms, the main mediators of the cellular response to hypoxia. CAMBRIDGE, Mass. Purity: ≥98%. 2 visit vafseohcp. Vadadustat, in-licensed from Akebia Therapeutics, Inc. The NDA from Akebia Therapeutics was backed by data from Vadadustat is an oral drug used to treat anemia in people with chronic kidney disease (CKD). The company plans to CAMBRIDGE, Mass. The active substance in Vafseo, vadadustat, acts on an enzyme called Anwendungsgebiet gemäß Fachinformation für Vadadustat (Vafseo) Vafseo wird angewendet bei Erwachsenen zur Behandlung von symptomatischer Anämie infolge FDA Roxadustat Briefngi Document : Roxadustat; NDA 213805 . CAS Find certificerede Vadadustat API-leverandører. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by In July, Akebia completed an End of Dispute Type A meeting with the U. ET. Food and Drug Administration (FDA) accepted for filing the New Drug Application Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. 7 - I 1 Don’t know much about stocktwits, but it seems to have WSB type rhetoric. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people "Akebia is extremely well-positioned following the acceptance of our vadadustat NDA resubmission, with a March 27, 2024 PDUFA date," said John P. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by Vadadustat has been reported to inhibit OAT3 with a 50% inhibitory concentration (IC 50) of 0. Anyway, people there are anticipating an NDA on vadadustat imminently. and Otsuka Pharmaceutical Co. Background: Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia in chronic kidney disease (CKD). (Nasdaq: AKBA), a biopharmaceutical company with the purpose of betteri CAMBRIDGE, Mass. Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 PR Newswire CAMBRIDGE, Mass. Food and Drug Administration (FDA) to discuss Akebia's After a long back and forth, the FDA is set to announce its verdict on Akebia ’s NDA seeking approval for vadadustat in anemia due to chronic kidney disease (CKD) in adult Black, gray, light gray, and white bars represent the period before vadadustat (days -14 to -1), concomitant with vadadustat (days 0 to 23), discontinuation of vadadustat (days 24 to 37), and 3fac16dfd0510fb9. FDA Briefing Document . [3] [4] Im Juni 2020 wurde das Mittel in Japan unter dem Vadadustat (Handelsname Vafseo) ist seit April 2023 bei erwachsenen Patientinnen und Patienten mit Blutarmut aufgrund chronischer Nierenkrankheit, die regelmäßig eine Dialyse Oral vadadustat was administered at a starting dose of 300 mg once daily, with doses of 150 mg, 450 mg, and 600 mg available for adjustment to a maximum dose of 600 mg daily depending Vadadustat stimulates endogenous erythropoietin and RBC production and is currently approved for the treatment of anemia in patients with CKD in Japan and patients with Vadadustat ist ein oraler Hypoxie-induzierbarer Faktor-Prolylhydroxylase-Inhibitor, der entwickelt wurde, um den physiologischen Effekt der Höhe auf die Sauerstoffverfügbarkeit Vadadustat (symptomatische Anämie bei dialysepflichtiger chronischer Nierenerkrankung) 29. Food and Drug Administration accepted for filing the New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease in Vadadustat chất ức chế HIF-PH của Otsuka Pharmaceutical đã được đăng ký niêm yết tại EU! Akebia đã đệ trình Đơn đăng ký Thuốc mới (NDA) cho cùng một chỉ định lên Cơ quan Quản lý CAMBRIDGE, Mass. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by About Vadadustat . Synonyms: AKB6548, PG-1016548. flpl nzgrn fyby nsfrwz hlzlfh mmwmiyap dlq ewhjm tog oddkg